Patents by Inventor Kenneth H. Grabstein
Kenneth H. Grabstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7625553Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: February 9, 2007Date of Patent: December 1, 2009Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Publication number: 20080214439Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: April 17, 2008Publication date: September 4, 2008Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis
-
Publication number: 20080200641Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: April 17, 2008Publication date: August 21, 2008Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis
-
Publication number: 20080125347Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: May 2, 2007Publication date: May 29, 2008Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn
-
Patent number: 7235240Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex.Type: GrantFiled: September 7, 2005Date of Patent: June 26, 2007Assignee: Amgen Inc.Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 7192935Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: November 28, 2000Date of Patent: March 20, 2007Assignee: Amgen Inc.Inventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 7067132Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: November 6, 2002Date of Patent: June 27, 2006Assignee: Immuner Corp.Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 7008624Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: May 25, 2000Date of Patent: March 7, 2006Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Publication number: 20040253587Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: ApplicationFiled: November 6, 2002Publication date: December 16, 2004Applicant: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6184359Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: November 9, 1998Date of Patent: February 6, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 6177079Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the B- or &ggr;subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed. including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: November 20, 1998Date of Patent: January 23, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6168783Abstract: Antagonists of mammalian interleukin-15 (“IL-l5”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: August 14, 1998Date of Patent: January 2, 2001Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6165466Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: August 14, 1998Date of Patent: December 26, 2000Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 6013480Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: August 14, 1998Date of Patent: January 11, 2000Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 5985262Abstract: Nucleic acid sequences which encode biologically active EMF, expression vectors which direct the expression of ETF, ETE polypeptides, antibodies which specffically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: February 3, 1997Date of Patent: November 16, 1999Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 5892001Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: October 4, 1996Date of Patent: April 6, 1999Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 5795966Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: February 22, 1995Date of Patent: August 18, 1998Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 5747024Abstract: Methods of enhancing a mammal's immune response to a vaccine antigen are disclosed. Interleukin-15 can be used as a vaccine adjuvant to enhance or potentiate the immune response to a vaccine. Compositions comprising an immunogenic amount of vaccine antigen and an immunogenicity-augmenting amount of IL-15 are also provided by the invention. IL-15 can be used alone in the invention or in concurrent or sequential combination with additional vaccine adjuvants.Type: GrantFiled: July 19, 1995Date of Patent: May 5, 1998Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Michael B. Widmer
-
Patent number: 5707616Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.Type: GrantFiled: October 4, 1996Date of Patent: January 13, 1998Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dirk M. Anderson, June R. Eisenman, Victor Fung, Charles Rauch
-
Patent number: 5681557Abstract: There is disclosed a method of treating microbial infections in microbially infected mammals and a method of augmenting antitumor immunotoxicity in a mammal comprising administering a therapeutically effective amount of IL-7 in a pharmaceutically acceptable carrier. There is further disclosed a method of stimulating macrophages to produce cytokines made by activated macrophages and a method for improving T cell presentation by a macrophage comprising administering a therapeutically effective amount of IL-7. Further, antimicrobial activity of macrophages can be improved by administering a combination of IL-7 and Interferon-.gamma..Type: GrantFiled: May 15, 1995Date of Patent: October 28, 1997Assignee: Sterling Winthrop Inc.Inventors: Kenneth H. Grabstein, Mark Alderson